Lopinavir plus ritonavir: a novel protease inhibitor combination for HIV infections

Authors: Tan, Darrell; Walmsley, Sharon

Source: Expert Review of Anti-Infective Therapy, Volume 5, Number 1, February 2007 , pp. 13-28(16)

Buy & download fulltext article:

Price: $73.00 plus tax (Refund Policy)

Abstract:

Lopinavir is a protease inhibitor (PI) for the treatment of HIV infection that was specifically designed to overcome the shortcomings of earlier agents in this class. It is the only PI coformulated with ritonavir, whose pharmacological boosting effect results in a highly potent, well-tolerated, clinically effective antiretroviral agent with a high genetic barrier to resistance. Lopinavir/ritonavir is a recommended first-line option for antiretroviral-naive patients initiating PI-based therapy, and has an equally important role in the management of treatment-experienced individuals. Its favorable pharmacological and clinical characteristics have recently prompted investigators to explore its potential novel applications in HIV monotherapy and double-boosted regimens.

Keywords: antiretroviral therapy; HIV; lopinavir; protease inhibitor; resistance; ritonavir; salvage therapy

Document Type: Research article

DOI: http://dx.doi.org/10.1586/14787210.5.1.13

Publication date: 2007-02-01

More about this publication?

Expert Review of Anti-infective Therapy provides expert reviews on therapeutics and diagnostics in the treatment of infectious disease. Coverage includes antibiotics, drug resistance, drug therapy, infectious disease medicine, antibacterial, antimicrobial, antifungal and antiviral approaches, and diagnostic tests.
Editorial Board
Information for Authors
Submit a Paper
Subscribe to this Title
Information for Advertisers
Terms & Conditions
Information for Librarians
Free Trials
ingentaconnect is not responsible for the content or availability of external websites